NLRP3 and Parkinson disease: Selnoflast (RO7486967), formerly named somalix/RG6418/IZD334, an orally potent, selective, and reversible small molecule NLRP3 inflammasome inhibitor, has completed the Phase 1b study in participants with Early Idiopathic Parkinson’s Disease [38].